Stock Track | Ali Health Soars 5.08% Intraday on Exclusive Launches of Innovative Drugs

Stock Track

Jul 03

Ali Health's stock soared 5.08% during intraday trading on Friday, extending its recent positive momentum in the market.

The surge follows the exclusive launch of two blockbuster innovative drugs on Ali Health's platform. Hengrui Medicine's Class 1 innovative drug Ruiming and Yangtze River Pharmaceutical's Class 1 new drug Taituotuo were simultaneously launched exclusively on the platform, reinforcing the company's positioning as a premier first-launch destination for new specialty drugs.

This development is seen as a strong validation of Ali Health's channel value and digital service capabilities in the commercialization of innovative pharmaceuticals. Management has previously identified the innovative drug category as the core growth driver, with FY2027 revenue growth guidance of 10% to 15% year-over-year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1185640961"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1185640961\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1185640961?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-03 09:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185640961","market":"nz","top_or_hot":-1,"title":"Stock Track | Ali Health Soars 5.08% Intraday on Exclusive Launches of Innovative Drugs","media":"Stock Track","content":"<p>Ali Health's stock soared 5.08% during intraday trading on Friday, extending its recent positive momentum in the market.</p><p>The surge follows the exclusive launch of two blockbuster innovative drugs on Ali Health's platform. Hengrui Medicine's Class 1 innovative drug Ruiming and Yangtze River Pharmaceutical's Class 1 new drug Taituotuo were simultaneously launched exclusively on the platform, reinforcing the company's positioning as a premier first-launch destination for new specialty drugs.</p><p>This development is seen as a strong validation of Ali Health's channel value and digital service capabilities in the commercialization of innovative pharmaceuticals. Management has previously identified the innovative drug category as the core growth driver, with FY2027 revenue growth guidance of 10% to 15% year-over-year.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ali Health Soars 5.08% Intraday on Exclusive Launches of Innovative Drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ali Health Soars 5.08% Intraday on Exclusive Launches of Innovative Drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-03 09:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ali Health's stock soared 5.08% during intraday trading on Friday, extending its recent positive momentum in the market.</p><p>The surge follows the exclusive launch of two blockbuster innovative drugs on Ali Health's platform. Hengrui Medicine's Class 1 innovative drug Ruiming and Yangtze River Pharmaceutical's Class 1 new drug Taituotuo were simultaneously launched exclusively on the platform, reinforcing the company's positioning as a premier first-launch destination for new specialty drugs.</p><p>This development is seen as a strong validation of Ali Health's channel value and digital service capabilities in the commercialization of innovative pharmaceuticals. Management has previously identified the innovative drug category as the core growth driver, with FY2027 revenue growth guidance of 10% to 15% year-over-year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00241","symbol_name":"阿里健康","start_time":0,"source_url":"","article_id":"1185640961","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185640961","pubTimestamp":1783043356,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Ali Health's stock soared 5.08% during intraday trading on Friday, extending its recent positive momentum in the market.The surge follows the exclusive launch of two blockbuster innovative drugs on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00241":"阿里健康"},"translate_title":"股票赛道|独家首发创新药阿里健康盘中大涨5.08%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00241":1},"content_text":"Ali Health's stock soared 5.08% during intraday trading on Friday, extending its recent positive momentum in the market.The surge follows the exclusive launch of two blockbuster innovative drugs on Ali Health's platform. Hengrui Medicine's Class 1 innovative drug Ruiming and Yangtze River Pharmaceutical's Class 1 new drug Taituotuo were simultaneously launched exclusively on the platform, reinforcing the company's positioning as a premier first-launch destination for new specialty drugs.This development is seen as a strong validation of Ali Health's channel value and digital service capabilities in the commercialization of innovative pharmaceuticals. Management has previously identified the innovative drug category as the core growth driver, with FY2027 revenue growth guidance of 10% to 15% year-over-year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}